AMERX provides skin and wound care products through its proprietary brands, AMERIGEL® Advanced Skin and Wound Care, HELIX3® Bioactive Collagen, and EXTREMIT-EASE®. As of May 2026, the stock price is $0.20 with a market capitalization of $1.64M. The company operates as a micro-cap OTC-traded medical device manufacturer serving the specialized wound and skin care market.
Cyborg Score Rationale
Procyon is a micro-cap OTC stock with minimal market capitalization ($1.64M as of May 2026) and limited recent development visibility. While the company maintains operations in wound care products with established brands, the lack of recent material news, minimal trading volume, and tiny scale indicate significant challenges in growth and capital access.
Top Insights
Procyon operates primarily through the AMERX brand with three main product lines: AMERIGEL wound care, HELIX3 collagen, and EXTREMIT-EASE compression garments
The company serves institutional healthcare channels including hospitals, clinics, nursing facilities, and home health agencies
Extreme micro-cap scale ($1.64M market cap as of May 2026) with OTC Pink Sheets trading suggests limited institutional investment and liquidity
Historical profitability reported through 2007; current financial performance and revenue trends not clearly disclosed in recent sources
Named Competitors
Leukoplast/ELASTOPLAST — Global wound care and adhesive products
ACTICOAT — Advanced wound care and surgical dressings
Tegaderm — Medical tape and wound dressing solutions
Open the full interactive Procyon Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.